ANXA11 and Cognitive impairment: The consistent cognitive impairment observed in ANXA11-ALS patients indicates that genetic screening for ANXA11 variants should be prioritized in ALS patients with cognitive symptoms, while comprehensive neuropsychological evaluation must be performed in all identified ANXA11 carriers.